| Susan Dagostino, APRN | |
|
40 Hart St, New Britain, CT 06052-1743 | |
| (860) 229-0100 | |
| (860) 225-2647 |
| Full Name | Susan Dagostino |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 26 Years |
| Location | 40 Hart St, New Britain, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093743908 | NPI | - | NPPES |
| 400001941CT01 | Other | CT | BLUE CROSS |
| 194100 | Other | CT | CONNECTICARE |
| 500008445 | Other | CT | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | E50759 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Group Inc | 1254233836 | 1251 |
News Archive
KPLU 88.5's "Humanosphere" blog reports on a "Diseases without Borders" forum held in Seattle on Tuesday at which Nils Daulaire, director of the Office of Global Affairs for the U.S. Department of Health and Human Services, stressed that global health is a domestic issue.
In efforts to educate the body to fight off cancer, researchers have found that some immune cells are "smarter" than others. Working with collections of human cells, Johns Hopkins Kimmel Cancer Center scientists tested kill-rates of two kinds of T-cells "primed" to home in on myeloma, a cancer of the bone marrow. Those that live in the bone marrow outperformed their counterparts circulating in the blood by more than 90 percent.
Every cell in the body has chromosomes with so-called telomeres, which are shortened over time and also through lifestyle choices such as smoking and obesity. Researchers have long speculated that the shortening of telomeres increases the risk of heart attack and early death. Now a large-scale population study in Denmark involving nearly 20,000 people shows that there is in fact a direct link, and has also given physicians a future way to test the actual cellular health of a person.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
› Verified 5 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
KPLU 88.5's "Humanosphere" blog reports on a "Diseases without Borders" forum held in Seattle on Tuesday at which Nils Daulaire, director of the Office of Global Affairs for the U.S. Department of Health and Human Services, stressed that global health is a domestic issue.
In efforts to educate the body to fight off cancer, researchers have found that some immune cells are "smarter" than others. Working with collections of human cells, Johns Hopkins Kimmel Cancer Center scientists tested kill-rates of two kinds of T-cells "primed" to home in on myeloma, a cancer of the bone marrow. Those that live in the bone marrow outperformed their counterparts circulating in the blood by more than 90 percent.
Every cell in the body has chromosomes with so-called telomeres, which are shortened over time and also through lifestyle choices such as smoking and obesity. Researchers have long speculated that the shortening of telomeres increases the risk of heart attack and early death. Now a large-scale population study in Denmark involving nearly 20,000 people shows that there is in fact a direct link, and has also given physicians a future way to test the actual cellular health of a person.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan Dagostino, APRN 40 Hart St, New Britain, CT 06052-1743 Ph: (860) 229-0100 | Susan Dagostino, APRN 40 Hart St, New Britain, CT 06052-1743 Ph: (860) 229-0100 |
News Archive
KPLU 88.5's "Humanosphere" blog reports on a "Diseases without Borders" forum held in Seattle on Tuesday at which Nils Daulaire, director of the Office of Global Affairs for the U.S. Department of Health and Human Services, stressed that global health is a domestic issue.
In efforts to educate the body to fight off cancer, researchers have found that some immune cells are "smarter" than others. Working with collections of human cells, Johns Hopkins Kimmel Cancer Center scientists tested kill-rates of two kinds of T-cells "primed" to home in on myeloma, a cancer of the bone marrow. Those that live in the bone marrow outperformed their counterparts circulating in the blood by more than 90 percent.
Every cell in the body has chromosomes with so-called telomeres, which are shortened over time and also through lifestyle choices such as smoking and obesity. Researchers have long speculated that the shortening of telomeres increases the risk of heart attack and early death. Now a large-scale population study in Denmark involving nearly 20,000 people shows that there is in fact a direct link, and has also given physicians a future way to test the actual cellular health of a person.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
› Verified 5 days ago
Jason Manto, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 85 Lafayette St, New Britain, CT 06051 Phone: 860-224-3642 | |
Kevin Jimenez, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5900 | |
Pramela Singson, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 85 Lafayette St, New Britain, CT 06051 Phone: 860-224-3642 | |
Mrs. Rosa Maria Kleinberg, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2150 Corbin Ave, New Britain, CT 06053 Phone: 860-223-2761 | |
Dorothy Forsyth, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 55 Winthrop St, New Britain, CT 06052 Phone: 860-224-6968 | |
Dante Goodwin, AGNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 55 Grand St, New Britain, CT 06052 Phone: 860-223-3617 |